Acute Coronary Syndrome
Conditions
Keywords
ACS
Brief summary
This study aims to describe antiplatelet therapy in ACS in Andalusia and make an assessment of efficacy and safety of hospital use Prasugrel / ticagrelor vs. Clopidogrel and Prasugrel switching to / ticagrelor patients pretreated with clopidogrel.
Detailed description
The management of acute coronary syndrome has changed in recent years as reflected in the new Clinical Practice Guidelines of the European Society of Cardiology for the management of ACS with or without ST segment elevation, with the development and increased accessibility of the angiography and percutaneous coronary intervention and the arrival of the new antiplatelet (Prasugrel and Ticagrelor). The ACS encompasses several clinical entities where dual antiplatelet therapy remains the basis of antiplatelet therapy and one of the mainstays of treatment. But the emergence of Prasugrel and Ticagrelor have changed the classical management with aspirin plus clopidogre
Interventions
None listed
Sponsors
Fundación Pública Andaluza Progreso y Salud
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients admitted to the Coronary Care Unit at the time defined with an initial diagnosis of ACS.
Exclusion criteria
* Myocarditis, Takotsubo syndrome, pulmonary thromboembolism. * Secondary MI or type 2, caused by an increase in demand or decrease oxygen (anemia, tachycardia, hypotension, heart failure, etc.). 11 * Patients under 18 years.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| type of antiplatelet were used | 12 months | There are the following therapeutic groups: Clopidogrel; Prasugrel; Ticagrelor; Switching to Prasugrel ; Switching toTicagrelor |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ischemic events after ACS during hospitalization | 3, 6 and 12 months | Ischemic event is defined as the combined end point of stroke, reinfarction, stent thrombosis, restenosis and stent injury retreat previously treated 1\. thrombotic complications: stroke, stent restenosis, retreat of the culprit vessel, stent thrombosis, CVA |
| Total rate of hemorrhage and severity thereof under TIMI9 and BARC15 classification. Also it included as a safety endpoint all-cause mortality. | 3, 6 and 12 months | bleeding complications: BARC, TIMI classification, transfusions, major bleedingbleeding complications: BARC, TIMI classification, transfusions, major bleeding |
Countries
Spain
Outcome results
None listed